What the heck?
mell, the drug dropped significantly in potential value wit the FDA approval of Avastin and Chemo for Ovarian. Roche is obviously not interested in partnering at this point until we show efficacy in triple therapy. We had a window of opportunity that slipped away and set us back a few years if not indefinitely.
I mean it's May now, a full year since he took over as CEO. How much has he communicated to shareholders since then? How many PR's in the past year? How far has CA4P moved toward eventual approval? How about that share price at multi year lows? Who needs more than 1 shot on goal when it's a good one? What's wrong with a reverse split anyways? We don't need Conference Calls - they're for sissies that have no confidence in their investment. I think shareholder value is way overrated!!! lol
Will 1:10 be enuf? Maybe 1:20 would be better?
Up we go now for te rest of the week, we have Q1 results next Tuesday and it promises t be exciting with ZOPTREX results on the doorstep and APIFINY blowing the doors off the hinges
Shorts started a over ahead of Q1